Myricetin inhibits IL-1beta-induced inflammatory mediators in SW982 human synovial sarcoma cells

Int Immunopharmacol. 2010 Jul;10(7):812-4. doi: 10.1016/j.intimp.2010.04.010. Epub 2010 Apr 18.

Abstract

Rheumatoid arthritis (RA) synovial fibroblasts produce inflammatory mediators, which destruct cartilage and bone in RA joint. The aim of this study is to investigate the effect of myricetin on inflammatory cytokine/matrix metalloproteinase (MMP) production and mitogen-activated protein kinases (MAPKs) in IL-1beta-stimulated SW982 synovial cells. Myricetin significantly decreased IL-1beta-induced production of IL-6 and MMP-1 in synovial cells. Moreover, myricetin diminished the phosphorylation of Jun NH2-terminal kinase (JNK) and p38 MAPK. These results suggest that myricetin reduces the production of MMP and IL-6 in SW982 cells by inhibiting MAPKs (JNK and p38).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Rheumatoid / drug therapy
  • Cell Line, Tumor
  • Enzyme Activation / drug effects
  • Fibroblasts / drug effects*
  • Fibroblasts / immunology
  • Fibroblasts / metabolism
  • Fibroblasts / pathology
  • Flavonoids / pharmacology*
  • Flavonoids / therapeutic use
  • Humans
  • Inflammation Mediators / metabolism
  • Interleukin-1beta / immunology
  • Interleukin-1beta / metabolism
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism*
  • Matrix Metalloproteinase 1 / genetics
  • Matrix Metalloproteinase 1 / metabolism*
  • Sarcoma, Synovial / drug therapy*
  • Sarcoma, Synovial / immunology
  • Sarcoma, Synovial / pathology
  • Signal Transduction / drug effects
  • Synovial Membrane / pathology
  • p38 Mitogen-Activated Protein Kinases / genetics
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Flavonoids
  • Inflammation Mediators
  • Interleukin-1beta
  • Interleukin-6
  • myricetin
  • p38 Mitogen-Activated Protein Kinases
  • Matrix Metalloproteinase 1